PARP-inhibitors (PARPi) are a novel drug class that proved to be effective in tumors harboring germline BRCA1/2 (gBRCA) mutations, by inhibiting PARP enzymes and trapping PARP1 on the DNA, ultimately leading to cancer cell death (1, 4). Here, PARP1 is linked to cancer.